Live Analyst Rating Changes 28470 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Patrick Dolezal
LIFE

Patrick Dolezal

LifeSci Capital
Wall Street Analyst
★★★★★
#308
on 13Foresight · ranked by our own returns
65%
Success Rate
+11.6%
Average Return
33 of 51 calls profitable · +7.1% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 65% of Patrick Dolezal's ratings turned a profit when each position was held for 1 year — averaging +11.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

93 Buy 0 Hold 0 Sell
Patrick's Stock Coverage 18 ratings · 2026-08-29
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
IBIO
Ibio
 Aug 28, 2026 BUY Strong Buy
+327.4% avg upside
11 analysts
$5.00
267.74% Upside
 · ·
SLGL
Sol-Gel Technologies
 Aug 22, 2026 BUY Strong Buy
+74.2% avg upside
6 analysts
$195.00
183.29% Upside
 -6.2% ·
SRZN
Surrozen
 Aug 17, 2026 BUY Strong Buy
+66.2% avg upside
8 analysts
$46.00
105.24% Upside
 +0.9% ·
KOD
Kodiak Sciences
 Aug 15, 2026 BUY Buy
+39.0% avg upside
11 analysts
$85.00
125.25% Upside
 -4.5% ·
ACHV
Achieve Life Sciences
 Aug 15, 2026 BUY Strong Buy
+90.1% avg upside
15 analysts
$17.00
109.81% Upside
 +8.9% ·
NGNE
Neurogene
 Aug 11, 2026 BUY Strong Buy
+32.2% avg upside
23 analysts
$63.00
72.24% Upside
 +5.8% ·
RCKT
Rocket Pharmaceuticals
 Aug 10, 2026 BUY Buy
+343.7% avg upside
29 analysts
$12.00
210.80% Upside
 -3.6% ·
OCS
Oculis Holding
 Aug 08, 2026 BUY Strong Buy
+205.6% avg upside
11 analysts
$41.00
235.80% Upside
 +3.7% ·
MBX
MBX Biosciences, Inc.
 Aug 08, 2026 BUY Strong Buy
+25.6% avg upside
14 analysts
$121.00
92.11% Upside
 +0.4% ·
GPCR
Structure Therapeutics, Inc. Sponsored ADR
 Aug 06, 2026 BUY Strong Buy
+117.2% avg upside
17 analysts
$104.00
119.54% Upside
 -6.2% ·
IMMX
Immix Biopharma
 Jun 17, 2026 BUY Strong Buy
+25.8% avg upside
9 analysts
$19.00
36.23% Upside
 +49.6% ·
TARS
Tarsus Pharmaceuticals
 Dec 11, 2023 BUY Strong Buy
+7.7% avg upside
16 analysts
$60.00
16.38% Downside
 +193.1% ·
YARW
Yarrow Bioscience
 Nov 11, 2023 BUY Strong Buy
-26.4% avg upside
9 analysts
$6.00
83.82% Downside
 -13.2% ·
LRMR
Larimar Therapeutics
 Aug 10, 2023 BUY Strong Buy
+342.4% avg upside
22 analysts
$14.00
249.23% Upside
 +101.6% ·
TNYA
Tenaya Therapeutics
 Mar 09, 2023 BUY Strong Buy
+1345.4% avg upside
11 analysts
$16.00
2218.53% Upside
 +119.2% ·
CLDX
Celldex
 Dec 11, 2022 BUY Strong Buy
+3.6% avg upside
28 analysts
$39.00
0.26% Downside
 -19.8% ·
IVA
Inventiva
 Mar 08, 2021 BUY Strong Buy
+235.2% avg upside
17 analysts
$25.00
431.29% Upside
 -18.3% ·
FR:IVA
Inventiva
 Jun 16, 2020 BUY Strong Buy
+328.2% avg upside
6 analysts
$25.00
525.08% Upside
 +2.2% ·
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Patrick Dolezal — Frequently Asked Questions
How accurate are Patrick Dolezal's stock ratings?
Based on the calls 13Foresight could measure, about 65% of Patrick's ratings were profitable over a one-year hold, with an average return of +11.6% per rating, or +7.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Patrick ranked on 13Foresight?
Patrick Dolezal is currently ranked #308 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Patrick cover?
Patrick most recently has ratings on IBIO, SLGL, SRZN, KOD, ACHV, NGNE, RCKT, OCS, MBX, GPCR, IMMX, TARS and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.